13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001631134
Total reported value
$1.9B
$1.9B
58 檔
27.2%
The Q3 2024 SEC filing reveals that Sofinnova Investments, Inc. held a total portfolio value of $1.9B, covering 58 public equity positions.
In Q3 2024, Sofinnova Investments, Inc. adopted a defensive or profit-taking posture, trimming 15 positions and completely liquidating 29 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NTRA | Natera Inc | Stock-Healthcare | 15.62% | +9.98% | — | |
| 2 | VERA | Vera Therapeutics Inc | Stock-Other | 9.80% | +1.93% | — | |
| 3 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 6.86% | — | +11.82% | |
| 4 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 5.00% | — | +1.00% | |
| 5 | IDYA | Ideaya Biosciences Inc | Stock-Other | 4.40% | +0.35% | +51.92% | |
| 6 | ELAN | Elanco Animal Health Inc | Stock-Healthcare | 4.10% | — | +22.85% | |
| 7 | BIOA | Bioage Labs Inc | Stock-Other | 3.80% | +1.39% | — | |
| 8 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 3.78% | -0.62% | +70.71% | |
| 9 | INCY | Incyte CORP | Stock-Healthcare | 3.75% | — | — | |
| 10 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.55% | -0.02% | EXIT | |
| 11 | RAPP | Rapport Therapeutics Inc | Stock-Other | 3.24% | +1.84% | +2.26% | |
| 12 | AVBP | Arrivent Biopharma Inc | Stock-Other | 3.16% | +1.56% | — | |
| 13 | YMABUSD | Y-mabs Therapeutics Inc | Stock-Other | 2.29% | — | — | |
| 14 | DYN | Dyne Therapeutics Inc | Stock-Other | 2.20% | +0.77% | -52.51% | |
| 15 | COGT | Cogent Biosciences Inc | Stock-Other | 1.94% | -1.02% | -18.32% | |
| 16 | SVRA | Savara Inc | Stock-Other | 1.91% | +0.04% | +2.79% | |
| 17 | NVS | Novartis Ag-sponsored Adr | Stock-Healthcare | 1.83% | — | — | |
| 18 | ✓ | Inozyme Pharma Inc | Stock-Other | 1.78% | — | — | |
| 19 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 1.67% | +0.25% | — | |
| 20 | INSM | Insmed Inc | Stock-Healthcare | 1.66% | -1.28% | +25.71% | |
| 21 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.20% | — | -63.46% | |
| 22 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.15% | +0.85% | — | |
| 23 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.06% | — | -83.43% | |
| 24 | BSX | Boston Scientific CORP | Stock-Healthcare | 0.90% | — | -20.61% | |
| 25 | PHVS | Pharvaris N.V. | Stock-Other | 0.88% | +0.70% | -0.20% | |
| 26 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.82% | +0.34% | -19.11% | |
| 27 | IMNM | Immunome Inc | Stock-Other | 0.79% | +0.47% | +3.22% | |
| 28 | GH | Guardant Health Inc | Stock-Healthcare | 0.74% | — | — | |
| 29 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.73% | — | -55.33% | |
| 30 | INBX | Inhibrx Biosciences Inc | Stock-Other | 0.67% | +0.44% | +15.70% | |
| 31 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 0.67% | — | -80.73% | |
| 32 | ✓ | Stock-Other | 0.62% | — | — | ||
| 33 | ✓ | Establishment Labs Holdings In | Stock-Other | 0.62% | -0.07% | EXIT | |
| 34 | MRNS* | Marinus Pharmaceuticals Inc | Stock-Other | 0.61% | — | +3.05% | |
| 35 | JANX | Janux Therapeutics Inc | Stock-Other | 0.59% | — | — | |
| 36 | CABA | Cabaletta Bio Inc | Stock-Other | 0.57% | — | +25.69% | |
| 37 | ACHV | Achieve Life Sciences Inc | Stock-Other | 0.57% | — | +9.05% | |
| 38 | KURA | Kura Oncology Inc | Stock-Other | 0.46% | — | -64.02% | |
| 39 | PAHC | Phibro Animal Health Corp-a | Stock-Other | 0.43% | — | +0.50% | |
| 40 | ILMN | Illumina Inc | Stock-Healthcare | 0.42% | — | — | |
| 41 | ERAS | Erasca Inc | Stock-Other | 0.40% | — | +8.42% | |
| 42 | ✓ | Immatics NV | Stock-Other | 0.35% | +0.56% | -51.54% | |
| 43 | NARIUSD | Inari Medical Inc | Stock-Other | 0.30% | — | -42.04% | |
| 44 | BDX | Becton Dickinson And Co | Stock-Healthcare | 0.29% | — | — | |
| 45 | NXTCEUR | Nextcure Inc | Stock-Other | 0.29% | — | — | |
| 46 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 0.28% | — | — | |
| 47 | EXK | Exact Sciences CORP | Stock-Materials | 0.20% | — | -79.30% | |
| 48 | IRON | Disc Medicine Inc | Stock-Other | 0.16% | +0.36% | +41.35% | |
| 49 | BOLT1EUR | Bolt Biotherapeutics Inc | Stock-Other | 0.14% | — | — | |
| 50 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.14% | — | +335.13% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NTRA | Natera Inc | +6.9% | — | Unchanged |
| 2 | VERA | Vera Therapeutics Inc | +4.6% | — | Unchanged |
| 3 | BIOA | Bioage Labs Inc | +3.8% | NEW | New buy |
| 4 | INCY | Incyte CORP | +3.8% | NEW | New buy |
| 5 | AXSM | Axsome Therapeutics Inc | +2.5% | +70.71% | Add |
| 6 | SLNOEUR | Soleno Therapeutics Inc | +2.4% | +59.89% | Add |
| 7 | IDYA | Ideaya Biosciences Inc | +2.3% | +51.92% | Add |
| 8 | NVO | Novo-nordisk A/s-spons Adr | +2% | +11.82% | Add |
| 9 | ELAN | Elanco Animal Health Inc | +2% | +22.85% | Add |
| 10 | NVS | Novartis Ag-sponsored Adr | +1.8% | NEW | New buy |
| 11 | AZNN | Astrazeneca Plc-spons Adr | +1.8% | +1.00% | Add |
| 12 | JAZZ | Jazz Pharmaceuticals plc | +1.7% | NEW | New buy |
| 13 | AVBP | Arrivent Biopharma Inc | +1.5% | — | Unchanged |
| 14 | RYTM | Rhythm Pharmaceuticals Inc | +1.2% | NEW | New buy |
| 15 | YMABUSD | Y-mabs Therapeutics Inc | +0.9% | — | Unchanged |
| 16 | RAPP | Rapport Therapeutics Inc | +0.9% | +2.26% | Add |
| 17 | INSM | Insmed Inc | +0.9% | +25.71% | Add |
| 18 | ✓ | Inozyme Pharma Inc | +0.8% | — | Unchanged |
| 19 | SVRA | Savara Inc | +0.8% | +2.79% | Add |
| 20 | GH | Guardant Health Inc | +0.7% | NEW | New buy |
| 21 | COGT | Cogent Biosciences Inc | +0.7% | -18.32% | Trim |
| 22 | JANX | Janux Therapeutics Inc | +0.6% | NEW | New buy |
| 23 | ILMN | Illumina Inc | +0.4% | NEW | New buy |
| 24 | IMNM | Immunome Inc | +0.4% | +3.22% | Add |
| 25 | EWTX | Edgewise Therapeutics Inc | +0.4% | -19.11% | Trim |
| 26 | MRNS* | Marinus Pharmaceuticals Inc | +0.4% | +3.05% | Add |
| 27 | INBX | Inhibrx Biosciences Inc | +0.3% | +15.70% | Add |
| 28 | ✓ | +0.3% | — | Unchanged | |
| 29 | BDX | Becton Dickinson And Co | +0.3% | NEW | New buy |
| 30 | PHVS | Pharvaris N.V. | +0.3% | -0.20% | Trim |
| 31 | TMO | Thermo Fisher Scientific Inc | +0.3% | NEW | New buy |
| 32 | ACHV | Achieve Life Sciences Inc | +0.2% | +9.05% | Add |
| 33 | BSX | Boston Scientific CORP | +0.2% | -20.61% | Trim |
| 34 | PAHC | Phibro Animal Health Corp-a | +0.2% | +0.50% | Add |
| 35 | ERAS | Erasca Inc | +0.2% | +8.42% | Add |
| 36 | GPCR | Structure Therapeutics Inc | +0.1% | +335.13% | Add |
| 37 | CABA | Cabaletta Bio Inc | +0.1% | +25.69% | Add |
| 38 | IRON | Disc Medicine Inc | +0.1% | +41.35% | Add |
| 39 | VIR | Vir Biotechnology Inc | +0.1% | NEW | New buy |
| 40 | NXTCEUR | Nextcure Inc | +0.1% | — | Unchanged |
| 41 | RNAGBP | Avidity Biosciences Inc | +0.1% | +42.23% | Add |
| 42 | CATX | Perspective Therapeutics Inc | +0.1% | -8.67% | Trim |
| 43 | REPL | Replimune Group Inc | 0% | NEW | New buy |
| 44 | CATBUSD | Astria Therapeutics Inc | 0% | +41.11% | Add |
| 45 | BOLT1EUR | Bolt Biotherapeutics Inc | 0% | — | Unchanged |
| 46 | LUNG | Pulmonx CORP | 0% | +3.43% | Add |
| 47 | ✓ | Immatics N.v | 0% | +5.11% | Add |
| 48 | ✓ | Ikena Oncology Inc | 0% | — | Unchanged |
| 49 | PDSB | Pds Biotechnology CORP | 0% | EXIT | Sold out |
| 50 | KYTX | Kyverna Therapeutics Inc | 0% | EXIT | Sold out |
According to official SEC Form 13F filings, Sofinnova Investments, Inc. reported a total U.S. public equity portfolio value of $1.9B across 58 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NTRA, VERA, NVO) accounted for 27.2% of total reported equity market value during Q3 2024.
Top New Position Initiated
BIOA
市值: $47.9M
Top Position Liquidated / Trimmed
QQQ
前期市值: $191.6M
During Q3 2024, Sofinnova Investments, Inc.'s top holdings by market value included NTRA (15.6%)、VERA (9.8%)、NVO (6.9%). The largest single position, NTRA, represented 15.6% of total portfolio value.
In Q3 2024, Sofinnova Investments, Inc. made 78 total portfolio adjustments, initiating 12 new buys, adding to 22 positions, trimming 15 holdings, and fully liquidating 29 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.